Navigation Links
China Medical Technologies Receives Two Patents Granted by the UKIPO and Notice of Allowance for Four Patent Applications from the USPTO
Date:10/11/2011

BEIJING, Oct. 11, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received two patents from the United Kingdom Intellectual Property Office (the "UKIPO") and Notice of Allowance for four patent applications from the United States Patent and Trademark Office (the "USPTO"). All patents relate to the Company's SPR technology.

Patent granted by the UKIPO

  • Patent No. GB2454852 – "A Method for Screening of Infectious Agents in Blood"
  • Patent No. GB2455929 – "A Method for the Identification of Human Immunodeficiency Virus Related Antibodies in Blood"

Notice of Allowance for patent application from the USPTO

  • Patent application No. 12/441,530 – "Method for Quantitative Detection of Diabetes Related Immunological Markers"
  • Patent application No. 12/441,710 – "Method of Surface Plasmon Resonance (SPR) to Detect Genomic Aberrations in Patients with Multiple Myeloma"
  • Patent application No. 12/442,379 – "Method for the Quantitative Evaluation of Sex Hormones in a Serum Sample"
  • Patent application No. 12/442,381 – "Method for Quantitative Measurement of Thyroid Related Antibodies or Antigens in a Serum Sample"

The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that a patent will be issued after completion of the administrative procedures by the applicant.

In addition, the Company has several patent applications under examination by the USPTO currently. The Company expects to receive the relevant Notice of Allowance from the USPTO within the next twelve months.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact

Winnie Yam
Tel: +852-2511-9808
Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, ... has announced the launch of an opioid management ... guidelines on opioids and helps stem the growing ... often prescribed to treat chronic non-cancer pain (back ... serious risks and lack of evidence regarding long-term ...
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... 19, 2017 Report Details ... Alzheimer,s Disease ... Companies – our new study reveals trends, R&D progress, ... events affecting the Alzheimer,s disease therapeutics and diagnostics market. ... key questions: - How is the Alzheimer,s disease therapeutics ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... 2017 , ... Salveo for life, a company that distributes an effervescent lime-flavored ... States as part of its presence to expand its market reach. , Using a ... productions of nasty toxins as a result of drinking alcohol, eliminating those toxins quickly, ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Seamild, the ... on the futuristic vision of its owner and founder. As Oat is recognized globally ... to everybody he knows personally as he believes it is a move to sow ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual ... alumni, family, friends, and community. “Coming Home 2017” will be held on ...
(Date:1/21/2017)... Santa Rosa, CA (PRWEB) , ... January 21, ... ... announce the opening of its new medical office in Petaluma, located at 167 ... full-service casting room, access to SRO sports medicine and rehabilitation services ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ line of bone ... performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for ...
Breaking Medicine News(10 mins):